Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT01722214

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01722214
Other papers using this trial's data
  • TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study The Journal of investigative dermatology, 2017-08 DOI, PubMed 28286061

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01722214. Randomized; triple masking; primary purpose prevention. Start 2012-11 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Condition
Psoriasis
Condition
Vascular Inflammation
Condition
Coronary Atherosclerosis
Intervention (Biological)
Adalimumab
Intervention (Other)
Placebo
Lead sponsor
Innovaderm Research Inc. (class: other)
Collaborator
Abbott (class: industry)
Collaborator
Montreal Heart Institute (class: other)

Record details

Record id
cardio:ct-nct01722214
Content hash
4959c083ed961ec6accd3180dfec1dcecdf2a12c78b77da11357882bcf96986f